All News

Obe-cel is an investigational CD19 CAR T-cell therapy currently in clinical trials for relapsed/refractory B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.

Management of heart failure focuses on avoiding reversible precipitants and optimizing guideline-directed therapy to lower mortality and hospitalizations.

Ribociclib (Kisqali) demonstrated a 26% risk reduction in distant disease-free survival and a 28% risk reduction in recurrence-free survival in patients with HR+/HER2- early breast cancer.

Upadacitinib 15 mg once daily had a better clinical response compared to adalimumab 40 mg every other week at 12 weeks in 3-year follow-up data among patients with rheumatoid arthritis.

Investigators found thinner ventricular walls, disorganized and ruptured myocardial fiber, mild inflammatory infiltration, and mild epicardia or interstitial fibrosis in the hearts of mice infected with COVID-19.

Research shows receipt of medications for chronic conditions was relatively stable in the first 2 years of the pandemic from 2020 to 2021 across racial and ethnic groups.

The 2023 ASCO Annual Meeting is being held in Chicago, Illinois from June 2 to 6.

Investigators previously reported a statistically significant improvement in radiographic progression-free survival in the full intention-to-treat population of adults with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer.

The primary medication therapies that can help with prophylaxis against HIV include pre-exposure prophylaxis and non-occupational post-exposure prophylaxis.

Available pharmacological therapies have shown high efficacy in achieving weight loss.

As patient access, public health advocates flex their muscles to reduce barriers to care, products, will that continue to translate in marketplace?

Psilocybin and other psychedelics hold promise in treating anxiety, depression, substance abuse and addiction, posttraumatic stress disorder, obsessive compulsive disorder, headaches, and chronic pain disorders.

The DEA’s decision allows some health care providers to have more leeway in prescribing certain controlled substances.

Navigating the Transition to Year-Round Immunization

Never have there been so many opportunities for non–dispensing pharmacist roles. At the same time, there has never been such a need to save the dispensing environment.

Pfizer Inc’s bivalent respiratory syncytial virus (RSV) vaccine Abrysvo is indicated to prevent lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

As the summer months approach, pharmacists can offer many services to ensure patients remain safe and healthy during their travels.

Former and current smokers showed higher mortality from early-stage non-small cell lung cancer than never smokers.

Pediatric drug development, which has a complex background and history, has fundamental catches based around how children are defined in the context of clinical studies.

Products include an antidepressant and treatment for hypertension.

As more becomes known about Crohn disease, treatment modalities have evolved with biologic monoclonal antibodies becoming a key part of guideline- and evidence-based medicine.

Radio frequency identification-enabled automation for inventory management has only achieved its massive adoption in the retail space over the past 2 decades.

The radiohybrid imaging agent allowed positron emission tomography to identify prostate cancer with an 83% detection rate.

Repotrectinib is a promising next-generation tyrosine kinase inhibitor under investigation for the treatment of ROS1-positive locally advanced or metastatic non-small cell lung cancer.

In the initial cohort, 63% of patients with advanced melanoma achieved an objective response rate, including 6 who had a complete response and 19 who had a partial response to the combination of fianlimab and cemiplimab.

Products include a new FDA-approved treatment for dermatitis in younger individuals and a continuous glucose monitoring sensor system.

Adagrasib is a RAS GTPase family inhibitor with objective response rate in patients with certain types of locally advanced or metastatic non–small cell lung cancer (NSCLC).